SELLAS Life Sciences Group, Inc. financial data

Symbol
SLS on Nasdaq
Location
7 Times Square, Suite 2503, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 448 % +273%
Debt-to-equity 26.8 % -89.4%
Return On Assets -75.1 % +58%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 142M shares +102%
Common Stock, Shares, Outstanding 125M shares +94.3%
Entity Public Float 68.6M USD +54.4%
Common Stock, Value, Issued 12K USD +100%
Weighted Average Number of Shares Outstanding, Basic 108M shares +58.8%
Weighted Average Number of Shares Outstanding, Diluted 108M shares +58.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Costs and Expenses 26.9M USD -17.8%
Operating Income (Loss) -26.9M USD +17.8%
Nonoperating Income (Expense) 995K USD +102%
Net Income (Loss) Attributable to Parent -25.9M USD +19.6%
Earnings Per Share, Basic 0 USD/shares +61.2%
Earnings Per Share, Diluted 0 USD/shares +61.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 44.3M USD +111%
Assets, Current 49.1M USD +104%
Operating Lease, Right-of-Use Asset 556K USD +8.38%
Goodwill 1.91M USD 0%
Assets 51.6M USD +94.5%
Accounts Payable, Current 2.31M USD -49.3%
Employee-related Liabilities, Current 1.42M USD -20.5%
Accrued Liabilities, Current 3.02M USD -45%
Liabilities, Current 5.93M USD -44.2%
Operating Lease, Liability, Noncurrent 0 USD
Liabilities 5.93M USD -44.2%
Retained Earnings (Accumulated Deficit) -267M USD -10.7%
Stockholders' Equity Attributable to Parent 45.6M USD +187%
Liabilities and Equity 51.6M USD +94.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.07M USD +15.7%
Net Cash Provided by (Used in) Financing Activities 23.6M USD -11.5%
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 125M shares +94.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 14.5M USD -8.65%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 44.4M USD +110%
Deferred Tax Assets, Valuation Allowance 20.9M USD +11%
Deferred Tax Assets, Gross 21.1M USD +10.9%
Operating Lease, Liability 599K USD +3.99%
Lessee, Operating Lease, Liability, to be Paid 635K USD +3.76%
Operating Lease, Liability, Current 599K USD +3.99%
Lessee, Operating Lease, Liability, to be Paid, Year Two 477K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 477K USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 36K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 14.1M USD +15.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Operating Lease, Payments 800K USD +60%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 200K USD +8.7%
Share-based Payment Arrangement, Expense 1.88M USD +11.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%